Status:
COMPLETED
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Lead Sponsor:
University of Leicester
Collaborating Sponsors:
Leicester Hospitals Charity
Francis Crick Institute
Conditions:
End Stage Kidney Disease
Eligibility:
All Genders
18+ years
Brief Summary
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic. It ...
Detailed Description
Patients with end stage kidney disease (ESKD) on haemodialysis are more likely to suffer poorer outcomes following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection...
Eligibility Criteria
Inclusion
- End stage kidney disease on haemodialysis
- Able and willing to give informed consent
- Have completed or due to complete vaccination against COVID-19
Exclusion
- Acute kidney injury requiring temporary haemodialysis
- Unable to give informed consent
- Pregnancy
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2022
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT04815850
Start Date
March 1 2021
End Date
December 5 2022
Last Update
September 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Leicester NHS Trust
Leicester, Leicestershire, United Kingdom, LE5 4PW